Form 10-Q · Quarterly report
CRH plc 10-Q, filed Oct 29, 2026
- Filed
- CIK
- 0000849395
- Accession no.
- 0000849395-26-000013
Summary
CRH plc's third-quarter 2026 revenue rose 3% to $11.4 billion while net income fell 22% to $1.2 billion, and the company completed its $8.5 billion acquisition of Arcosa. CRH's board authorized a new share buyback program of up to $6 billion expiring at the end of 2030 and declared a fourth quarterly dividend of $0.39 per share.
Key points
- Q3 2026 total revenues were $11.4 billion, up 3% year over year, while net income was $1.2 billion compared with $1.5 billion and adjusted EBITDA was $2.7 billion, flat year over year.
- For the first nine months of 2026, total revenues were $29.5 billion, up 5%, net income was $2.5 billion compared with $2.8 billion, and adjusted EBITDA was $5.9 billion, up 4%.
- On October 23, 2026, CRH completed its acquisition of Arcosa, with Arcosa stockholders receiving $150.00 per share in cash and a total enterprise value of approximately $8.5 billion.
- CRH's board authorized a new share buyback program of up to $6 billion expiring at the end of 2030 and declared a fourth quarterly dividend of $0.39 per share.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
Item 2. Management’s Discussion Overview CRH is the leading provider of building materials critical to modernizing infrastructure. Our unmatched scale, connected portfolio, and deep local relationships make us the partner of choice for transportation, water and reindustrialization projects, shaping communities for a better tomorrow. CRH’s connected portfolio supplies building materials across the construction value chain, better serving our customers’ needs and driving repeat business while making construction simpler, safer and more sustainable. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.